PUBLISHER: Acute Market Reports | PRODUCT CODE: 1255973
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1255973
Psoriatic Arthritis Treatment Market Is Projected to Expand At A CAGR Of 7.5% Between 2023 And 2031. The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease that primarily affects the skin. Majorly 30% of the patients suffering from psoriasis develop psoriatic arthritis during the later stages of the disease. Psoriatic arthritis affects men and women equally with a global prevalence rate of 6 per 100,000 people. It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans. The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors. The occurrence is high in the Caucasian populations of North America and Europe followed by Asia Pacific.
According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering from psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis. The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.) and Aprelimast (Celgene Corporation), and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2022 to 2030 and capitalize the psoriatic arthritis treatment market.
Key players identified for the psoriatic arthritis treatment market include:
Abbvie, Inc., Amgen, Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F.Hoffman La-Roche AG, Janssen Global Services, Merck & Co., Novartis AG, Valeant Pharmaceuticals International, Inc. and Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Psoriatic Arthritis Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Psoriatic Arthritis Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Class
TNF Inhibitors
Interleukin Inhibitors
PDE4 Inhibitors
Others
Route of Administration
Oral
Parenteral
Topical
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Psoriatic Arthritis Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Psoriatic Arthritis Treatment market?
Which is the largest regional market for Psoriatic Arthritis Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Psoriatic Arthritis Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Psoriatic Arthritis Treatment market worldwide?